BANGLADESH’S first homegrown COVID-19 vaccine has obtained clearance for human trials in Phase I, reported Xinhua.
The Bangavax vaccine, developed by local pharmaceutical company Globe Biotech, on Sunday received clearance from the Directorate-General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities reviewed all the documents on all the previous trials.
“We’ve got the approval for Phase I clinical trial of Bangavax,” Mohammad Mohiuddin, a senior official at Globe Biotech, told reporters.
He said the trial would be conducted among 60 healthy volunteers at Bangabandhu Sheikh Mujib Medical University Hospital in Dhaka.
In November last year, Bangavax, a single-dose COVID-19 vaccine, got ethical clearance from the Bangladesh Medical Research Council for a human trial on up to 64 healthy adult participants.
Globe Biotech applied for approval for a human trial on Nov 1 last year, saying its vaccine has yielded “good results” in trials on monkeys.
The vaccine can reportedly be stored at a temperature of 4°C for one month and of -20°Cs for up to six months. – July 19, 2022
